Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Sam Citron who wrote (7583)	12/22/2002 12:11:52 PM
From: Biomaven	Read Replies (2) \| Respond to of 52153

Sam, I've owned a little Novartis for about a year. The patent expiration issues for most pharma are still too significant to make them very attractive, although of course prices are way down. BMY and SGP are interesting takeover candidates, although I doubt if they will do too much on their own. Quite a lot will depend on what we see on the political front in terms of Medicare prescription benefits. We might see more total money for drugs at the expense of pressure on prices. Frist is friendly to the pharma - he's the one that apparently drafted the recent Lilly legal bonanza. (I personally think the provision he drafted was sensible - unless vaccine makers have reasonable protection against suits we just will not see any new vaccines. I'd feel differently if I thought the legal system could render a fair verdict here, but I don't - the grieving parents will win jury verdicts in friendly venues every time against the giant greedy pharma). Peter